Inhalte
Startseite > Köpfe am DRFZ > Prof. Dr. Max Löhning

Prof. Dr. Max Löhning

Programmbereich 3, PB 3 – Systemrheumatologie

Gruppenleitung: Pitzer-Labor für Athroseforschung

Liaisonarbeitsgruppe mit Charité - Rheumatologie und Klinische Immunologie

+49/ 30/ 28460-760, Lab: -700/-711/-729

loehning@drfz.de

Scientific Background

Since 2015
Full Professor (W3), Head of Pitzer Laboratory of Osteoarthritis Research

2013 – 2014
Offer of Head of Department of Immunology (W3) at Universitätsmedizin Greifswald; 2014 declined

2006 – 2015
Lichtenberg Professor (W2) of Experimental Immunology, Charité, Berlin

2002 – 2006
Postdoctoral fellow with R.M. Zinkernagel and H. Hengartner at the Institute of Experimental Immunology, ETH and University Hospital Zurich, Switzerland

2000 – 2002
Postdoctoral fellow with A. Radbruch at DRFZ Berlin

1996 – 2000
PhD thesis at the Institute of Genetics, Univ. of Cologne; 2000 Dr. rer. nat.

1990 – 1996
Biology studies at the University of Mainz; 1996 Diploma (“with distinction”)

Since 2020
Guest Professor at Goethe-Universität Frankfurt/Main, Medical Faculty

Since 2013
Member of Berlin-Brandenburg Academy of Sciences (BBAW)

2004 – 2009
Member of Die Junge Akademie (The German Young Academy) at the BBAW and the German National Academy of Sciences Leopoldina

Since 2023
Chair of the Foundation Council of Schering Foundation

Since 2017
Board member and Council member of Berlin-Brandenburg Academy of Sciences (BBAW)

Since 2017
Spokesperson of the class Biological Sciences and Medicine of Berlin-Brandenburg Academy of Sciences (BBAW); 2014–2017 Vice-Spokesperson

Since 2017
Board member of Deutsche Rheumastiftung of German Society for Rheumatology (DGRh)

Since 2012
Vice-Director of Research Center ImmunoSciences (RCIS) at Charité

2010
Georges-Köhler-Prize of the German Society for Immunology (DGfI)

2006 – 2015
Lichtenberg Professorship at Charité funded by Volkswagen Foundation

2004
Robert-Koch-Postdoctoral-Prize of Robert Koch Foundation

2002 – 2004
Postdoctoral fellowship of Ernst Schering Foundation

2002
Avrion-Mitchison-Prize for Rheumatology

2000
Otto-Westphal-PhD-Prize of the German Society for Immunology

1993 – 2000
Diploma and PhD fellowships of the German National Academic Foundation

AG Löhning

Pitzer-Labor Arthroseforschung: Molekulare Schalter zur biologischen Gelenkregeneration

News

Go to end of slider
Mehr zeigen

Projekte

Top 5 Publikationen der Karriere

Plasticity and lineage commitment of individual TH1 cells are determined by stable T-bet expression quantities Hegazy, A.N., C. Peine, D. Niesen, I. Panse, Y. Vainshtein, C. Kommer, Q. Zhang, T.M. Brunner, M. Peine, A. Fröhlich, N. Ishaque, R.M. Marek, J. Zhu, T. Höfer & M. Löhning. Plasticity and lineage commitment of individual Th1 cells are determined by stable T-bet expression quantities. Science Advances 2024, 10:eadk2693. doi: 10.1126/sciadv.adk2693.
A type 1 immunity-restricted promoter of the IL-33 receptor gene directs antiviral T-cell responses Brunner*, T.M., S. Serve*, A.F. Marx, J. Fadejeva, P. Saikali, M. Dzamukova, N. Durán-Hernández, C. Kommer, F. Heinrich, P. Durek, G.A. Heinz, T. Höfer, M.F. Mashreghi, R. Kühn, D.D. Pinschewer & M. Löhning. A type 1 immunity-restricted promoter of the IL-33 receptor gene directs antiviral T-cell responses. Nature Immunology 2024, 25:256-267. doi: 10.1038/s41590-023-01697-6. (*Shared first authors). [Paper of the Months of Charité Faculty Board, March 2024]
NOS inhibition reverses TLR2-induced chondrocyte dysfunction and attenuates age-related osteoarthritis Shen, P., S. Serve, P. Wu, X. Liu, Y. Dai, N. Durán-Hernández, D.T.M. Nguyen, M. Fuchs, T. Maleitzke, M.J. Reisener, M. Dzamukova, K. Nussbaumer, T.M. Brunner, Y. Li, V. Holecska, G.A. Heinz, F. Heinrich, P. Durek, G. Katsoula, C. Gwinner, T. Jung, E. Zeggini, T. Winkler, M.F. Mashreghi, M. Pumberger, C. Perka & M. Löhning. NOS inhibition reverses TLR2-induced chondrocyte dysfunction and attenuates age-related osteoarthritis. Proceedings of the National Academy of Sciences USA 2023, 120:e2207993120. doi: 10.1073/pnas.2207993120.
The alarmin interleukin-33 promotes the expansion and preserves the stemness of Tcf-1+ CD8+ T cells in chronic viral infection Marx*, A.F., S.M. Kallert*, T.M. Brunner*, J.A. Villegas, F. Geier, J. Fixemer, T. Abreu-Mota, P. Reuther, W.V. Bonilla, J. Fadejeva, M. Kreutzfeldt, I. Wagner, P. Aparicio-Domingo, L. Scarpellino, M. Charmoy, D.T. Utzschneider, C. Hagedorn, M. Lu, K. Cornille, K. Stauffer, F. Kreppel, D. Merkler, D. Zehn, W. Held, S.A. Luther, M. Löhning** & D.D. Pinschewer**. The alarmin interleukin-33 promotes the expansion and preserves the stemness of Tcf-1+ CD8+ T cells in chronic viral infection. Immunity 2023, 56:813-828. doi: 10.1016/j.immuni.2023.01.029. (*Shared first authors, **Shared corresponding authors).
Mechanical forces couple bone matrix mineralization with inhibition of angiogenesis to limit adolescent bone growth Dzamukova, M., T. Brunner, J. Miotla-Zarebska, F. Heinrich, L. Brylka, M.F. Mashreghi, A. Kusumbe, R. Kühn, T. Schinke, T. Vincent & M. Löhning. Mechanical forces couple bone matrix mineralization with inhibition of angiogenesis to limit adolescent bone growth. Nature Communications 2022, 13:3059. doi: 10.1038/s41467-022-30618-8. [Avrion-Mitchison-Prize for Rheumatology to Maria Dzamukova, Dec. 2022]